Boulevard Bio
Boulevard Bio is a biotechnology company founded by Deerfield Management that develops novel therapies for cardiometabolic disorders.
Boulevard Bio is a biotechnology company founded by Deerfield Management that develops novel therapies for cardiometabolic disorders.
Boulevard Bio has raised $65.0M across 1 round. Its most recent round was a Seed of $65.0M in Aug 2026. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles, verified email addresses and LinkedIn profiles.
Boulevard Bio is featured in
Similar companies
Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine.
Syngenis Labs is committed to helping businesses and research organizations with their diagnostic and therapeutic development.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.